EP1713819A4 - Methods and compositions for combination rnai therapeutics - Google Patents

Methods and compositions for combination rnai therapeutics

Info

Publication number
EP1713819A4
EP1713819A4 EP05713043A EP05713043A EP1713819A4 EP 1713819 A4 EP1713819 A4 EP 1713819A4 EP 05713043 A EP05713043 A EP 05713043A EP 05713043 A EP05713043 A EP 05713043A EP 1713819 A4 EP1713819 A4 EP 1713819A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
rnai therapeutics
combination rnai
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05713043A
Other languages
German (de)
French (fr)
Other versions
EP1713819A2 (en
Inventor
Bao-Jian Li
Patrick Y Lu
Martin C Woodle
Frank Y Xie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Silence Therapeutics PLC
Original Assignee
Intradigm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intradigm Corp filed Critical Intradigm Corp
Publication of EP1713819A2 publication Critical patent/EP1713819A2/en
Publication of EP1713819A4 publication Critical patent/EP1713819A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
EP05713043A 2004-02-05 2005-02-07 Methods and compositions for combination rnai therapeutics Withdrawn EP1713819A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54177604P 2004-02-05 2004-02-05
PCT/US2005/003858 WO2005076999A2 (en) 2004-02-05 2005-02-07 Methods and compositions for combination rnai therapeutics

Publications (2)

Publication Number Publication Date
EP1713819A2 EP1713819A2 (en) 2006-10-25
EP1713819A4 true EP1713819A4 (en) 2007-11-14

Family

ID=34860217

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05713043A Withdrawn EP1713819A4 (en) 2004-02-05 2005-02-07 Methods and compositions for combination rnai therapeutics

Country Status (5)

Country Link
EP (1) EP1713819A4 (en)
CN (1) CN101044152A (en)
AU (1) AU2005213485A1 (en)
CA (1) CA2555531A1 (en)
WO (1) WO2005076999A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8491914B2 (en) * 2004-02-13 2013-07-23 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for delivery of interference RNA
WO2006121464A2 (en) * 2004-11-05 2006-11-16 Intradigm Corporation Compositions for treating respiratory viral infections and their use
CA2594334A1 (en) 2005-01-07 2006-07-13 Alnylam Pharmaceuticals, Inc. Rnai modulation of rsv and therapeutic uses thereof
BRPI0610499A2 (en) * 2005-04-12 2010-06-22 Intradigm Corp nucleic acid molecules, compositions and uses of said molecules
WO2007025254A2 (en) * 2005-08-26 2007-03-01 Henry Ford Health System Investigation and treatment of cancer using a g-protien coupled eicosnoid receptor
EP1970078A4 (en) * 2006-01-11 2010-11-17 Kyowa Hakko Kirin Co Ltd Composition inhibiting the expression of target gene in eyeball and remedy for disease in eyeball
US20100279408A1 (en) * 2006-11-27 2010-11-04 Enzon Pharmaceuticals, Inc. Polymeric short interfering rna conjugates
JP2010512786A (en) * 2006-12-21 2010-04-30 イントラダイム コーポレイション Inhibitory polynucleotide compositions and methods for treating cancer
DK2308514T3 (en) 2007-03-23 2013-09-02 To Bbb Holding B V Conjugates for targeted drug transport through the blood-brain barrier
RU2501803C2 (en) * 2007-10-01 2013-12-20 Айзис Фармасьютикалз, Инк. Compositions and methods of modulation of expression of receptor of growth factor of fibroblasts 4 (fgfr4)
US8735567B2 (en) 2007-11-06 2014-05-27 Patrick Y. Lu Multi-targeted RNAi therapeutics for scarless wound healing of skin
WO2009151539A1 (en) 2008-05-24 2009-12-17 Sirnaomics, Inc. COMPOSITIONS AND METHODS USING siRNA MOLECULES FOR TREATMENT OF GLIOMAS
US9012622B2 (en) 2008-12-31 2015-04-21 Patrick Y. Lu Compositions and methods using siRNA molecules and siRNA cocktails for the treatment of breast cancer
WO2011140285A2 (en) 2010-05-04 2011-11-10 Sirnaomics, Inc. Combinations of tgfbeta and cox-2 inhibitors and methods for their therapeutic application
WO2012016139A2 (en) 2010-07-29 2012-02-02 Sirnaomics, Inc. Sirna compositions and methods for treatment of hpv and other infections
CN103597074A (en) 2011-06-16 2014-02-19 Isis制药公司 Antisense modulation of fibroblast growth factor receptor 4 expression
CN103007291B (en) * 2011-09-26 2015-04-29 苏州圣诺生物医药技术有限公司 Composition for treating eye diseases by double-target/multi-target small nucleic acid and applications of composition
CN102399820B (en) * 2011-09-27 2013-06-12 天津佰思普生物科技有限公司 Small interfering RNA directed at HPV16 E7 gene and its application
US9868952B2 (en) 2012-07-08 2018-01-16 Sirnaomics, Inc. Compositions and methods for “resistance-proof” SiRNA therapeutics for influenza
EP3265493B1 (en) 2015-03-02 2024-01-10 180 Therapeutics LP Method of treating a localized fibrotic disorder using an il-33 antagonist
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
CN106771252A (en) * 2017-01-13 2017-05-31 福建医科大学 Application and kit of the AMACR albumen in prognosis evaluation reagent kit after preparing Liver Cancer Operation
CN111620939B (en) * 2019-10-25 2021-01-01 南京市妇幼保健院 Polypeptide ZYX for treating or assisting in treating ovarian cancer36-58
BR112022014578A2 (en) * 2020-01-23 2022-09-13 Sirnaomics Inc COMPOSITION AND METHODS OF PROPHYLATIC AND THERAPEUTIC RNAI FOR THE TREATMENT OF SEVERE ACUTE RESPIRATORY INFECTION CAUSED BY THE NEW CORONA VIRUS 2019 (2019-NCOV)
CN114196785A (en) * 2020-09-18 2022-03-18 北京大学人民医院 Biomarker for susceptibility of cytomegalovirus to megakaryocytes after allogeneic hematopoietic stem cell transplantation and application thereof
CN114452393A (en) * 2022-02-22 2022-05-10 南方科技大学 Application of PINCH-1 protein as target in preparation of medicine for treating pulmonary fibrosis
CN116421616A (en) * 2022-03-17 2023-07-14 圣诺生物医药技术(苏州)有限公司 Nucleic acid interference pharmaceutical composition and medicine for treating colorectal cancer, gastric cancer and prostate cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003106630A2 (en) * 2002-06-12 2003-12-24 Ambion, Inc. Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
WO2005019410A2 (en) * 2003-04-25 2005-03-03 Intradigm Corporation Rnai agents for anti-sars coronavirus therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003106630A2 (en) * 2002-06-12 2003-12-24 Ambion, Inc. Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
WO2005019410A2 (en) * 2003-04-25 2005-03-03 Intradigm Corporation Rnai agents for anti-sars coronavirus therapy

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
HAASNOOT P C JOOST ET AL: "Inhibition of virus replication by RNA interference.", JOURNAL OF BIOMEDICAL SCIENCE. 2003, vol. 10, no. 6 Pt 1, 2003, pages 607 - 616, XP002413217, ISSN: 1021-7770 *
HE M-L ET AL: "INHIBITION OF SARS-ASSOCIATED CORONAVIRUS INFECTION AND REPLICATION BY RNA INTERFERENCE", JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, CHICAGO,IL, US, vol. 290, no. 20, 26 November 2003 (2003-11-26), pages 2665 - 2666, XP009041436, ISSN: 0098-7484 *
JI J ET AL: "Enhanced gene silencing by the application of multiple specific small interfering RNAs", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 552, no. 2-3, 25 September 2003 (2003-09-25), pages 247 - 252, XP004460905, ISSN: 0014-5793 *
LEE N S ET AL: "Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 19, May 2002 (2002-05-01), pages 500 - 505, XP002965489, ISSN: 1087-0156 *
YU JENN-YAH ET AL: "Simultaneous inhibition of GSK3alpha and GSK3beta using hairpin siRNA expression vectors.", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY. FEB 2003, vol. 7, no. 2, February 2003 (2003-02-01), pages 228 - 236, XP002413216, ISSN: 1525-0016 *
ZHANG RENLI ET AL: "Inhibiting severe acute respiratory syndrome-associated coronavirus by small interfering RNA", CHINESE MEDICAL JOURNAL / ZHONGHUA YIXUE ZAZHI YINGWEN BAN, CHINESE MEDICAL ASSOCIATION, BEIJING, CN, vol. 116, no. 8, August 2003 (2003-08-01), pages 1262 - 1264, XP002310170, ISSN: 0366-6999 *

Also Published As

Publication number Publication date
WO2005076999A3 (en) 2006-07-06
CN101044152A (en) 2007-09-26
AU2005213485A1 (en) 2005-08-25
EP1713819A2 (en) 2006-10-25
CA2555531A1 (en) 2005-08-25
WO2005076999A2 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
EP1713819A4 (en) Methods and compositions for combination rnai therapeutics
EP1895838A4 (en) Compositions and methods
IL195619A0 (en) Compositions and methods for joininig non-conjoined iumens
GB0522287D0 (en) Method and compositions
EP1968526A4 (en) Foamable dental compositions and methods
GB0525314D0 (en) Method and composition
EP2101731A4 (en) Endoxifen methods and compositions
EP2037743A4 (en) Dough compositions and related methods
EP1763358A4 (en) Appetite-suppressing compositions and methods
GB0520990D0 (en) Improvements in lavatory block compositions
EP2088865A4 (en) Guggulphospholipid methods and compositions
GB0617171D0 (en) Novel compositions and methods
IL184062A0 (en) Visco-supplement composition and methods
SI2061458T1 (en) Topiramate compositions and methods for their use
GB0524927D0 (en) Compositions and method
IL195817A0 (en) Use of 2-benzoyl-imidazopyridines in therapeutics
EP1807512A4 (en) Compositions and methods for reverse transcription
GB0417359D0 (en) Improvements in compositions
ZA200802969B (en) Composition and method
PL2132251T3 (en) Composition and method
GB0625208D0 (en) Composition and method
GB0522655D0 (en) Composition and method
EP1976566A4 (en) Compositions and methods for altering rnai
GB0501348D0 (en) Compositions and methods
GB0511235D0 (en) Compositions and method

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060809

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/11 20060101AFI20070707BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1100143

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20071017

17Q First examination report despatched

Effective date: 20080313

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090707

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1100143

Country of ref document: HK